Primer: Biohaven ( BHVN US) - Nov 2025
Biohaven is a clinical-stage biopharmaceutical company that emerged from the acquisition of its migraine franchise by Pfizer, now focusing on a...
401 Views
Biopharma Week in Review MFN Fears Overdone but Medicare Negotiation Changes Reapplied Pressure
President Trump’s MFN executive order lacked a clear plan to lower drug prices, with any immediate moves likely facing legal challenges.
251 Views
CHMP Meeting Update April 2025: Sixteen New Medicines Recommended For Approval
Among the new medicines, Vertex’s triple combination CF drug Alyftrek, Amgen’s Thyroid eye disease drug Tepezza, and Jazz Pharmaceutical’s cancer...
494 Views
Biopharma Week in Review
RFK Jr. was confirmed as HHS Secretary a day before health agencies were hit by the broad federal layoffs ordered by Trump.
201 Views
Biopharma Week in Review - October 14, 2024
We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A. Last week, SRRK gained from...
372 Views